Please use this identifier to cite or link to this item:
Title: Anti-phosphatidylserine/prothrombin antibodies at two points: Correlation with lupus anticoagulant and thrombotic risk marker
Author: Egri, Natalia
Bentow, Chelsea
Rubio, Laura
Norman, Gary L.
López Sañudo, Susana
Mahler, Michael
Pérez Isidro, Albert
Cervera i Segura, Ricard, 1960-
Viñas, Odette
Espinosa, Gerard
Ruiz Ortiz, Estíbaliz
Keywords: Fosfolípids
Anticoagulants (Medicina)
Factors de risc en les malalties
Obesitat mòrbida
Complicacions en l'embaràs
Anticoagulants (Medicine)
Risk factors in diseases
Morbid obesity
Complications of pregnancy
Issue Date: 21-Oct-2021
Publisher: Frontiers Media
Abstract: Patients with autoimmune diseases (ADs) are a challenge for the intensivist; it is hard to differentiate among infection, disease activity, and combinations of both, leading to high mortality. This study is a retrospective analysis of 124 critically ill patients admitted to the intensive care unit (ICU) in a university hospital between 2008 and 2016. Bivariate case-control analysis was performed, using patients who died as cases; later, analysis using a logistic regression model with variables that were associated with mortality was conducted. Four variables were consistently associated with mortality in the logistic regression model and had adequate prediction value (Hosmer and Lemeshow statistic = 0.760; Nagelkerke R-squared = 0.494). The risk of death was found to be statistically associated with the following: shock at admission to ICU [odds ratio (OR): 7.56; 95% confidence interval (CI): 1.78-31.97, p = 0.006], hemoglobin level <8 g/dL (OR: 16.12; 95% CI: 3.35-77.52, p = 0.001), use of cytostatic agents prior to admission to the ICU (OR: 8.71; 95% CI: 1.23-61.5, p = 0.03), and low levels ofcomplement C3 (OR: 5.23; 95% CI: 1.28-21.35, p = 0.02). These variables can guide clinicians in the early identification of patients with AD with increased risk of death during hospitalization, leading to initial therapies seeking to improve survival. These results should be evaluated prospectively in future studies to establish their predictive power.
Note: Reproducció del document publicat a:
It is part of: Frontiers in Immunology, 2021, vol. 12, p. 754469
Related resource:
ISSN: 1664-3224
Appears in Collections:Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)
Articles publicats en revistes (Medicina)

Files in This Item:
File Description SizeFormat 
719931.pdf1.4 MBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons